Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMichael J Morris, R Bryan Rumble, Ethan Basch, et al.
Urologic Oncology|July 17, 2014
Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomyPiotr Zareba, Laurel Patterson, Rishikesh Pandya, et al.
Current Opinion in Molecular Therapeutics|February 6, 2004
Overview of phase I studies of intravenous administration of PV701, an oncolytic virusRobert M Lorence, Andrew L Pecora, Pierre P Major, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
MDM Policy & Practice|November 12, 2025
Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice ExperimentJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMichael J Morris, R Bryan Rumble, Ethan Basch, et al.
Urologic Oncology|July 17, 2014
Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomyPiotr Zareba, Laurel Patterson, Rishikesh Pandya, et al.
Current Opinion in Molecular Therapeutics|February 6, 2004
Overview of phase I studies of intravenous administration of PV701, an oncolytic virusRobert M Lorence, Andrew L Pecora, Pierre P Major, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerKim N Chi, Lillian L Siu, Hal Hirte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerKim N Chi, Sebastien J Hotte, Evan Y Yu, et al.
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
MDM Policy & Practice|November 12, 2025
Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice ExperimentJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
Pageof 9